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Electrophysiologic and hemodynamic studies were per-
formed before and after intravenous infusion of a new
antiarrhythmic agent, propafenone, in 28 patients with
recurrent ventricular tachycardia. Propafenone was given
at a loading dose of 2 mg/kg in all patients. Subsequently,
group A, the first 14 patients, received 1 mg/min and
group B, the second 14 patients, received 2 mg/min con-
tinuous infusion. Propafenone exerted no effect on sinus
nodal recovery time and sinoatrial conduction time, but
significantly prolonged atrioventricular (AV) nodal and
His-Purkinje conduction time and the QRS duration (re-
spectively,95 ± 19,48 ± 10 and 120 ± 23 ms before,
and 110 ± 28, 53 ± 10 and 135 ± 27 ms after; p <
0.001). Propafenone did not change the mean arterial
blood pressure but slightly increased right atrial, pul-
monary artery and capillary wedge pressures resulting
in mild depression of the cardiac index (2.6 ± 0.8 li-
The medical management of patients with recurrent ven-
tricular tachycardia, a harbinger of sudden death, has been
less than satisfactory. Conventional agents are frequently
ineffective. Experimental agents are sometimes more effi-
cacious, but are associated with increased side effects (I).
Propafenone* is a new antiarrhythmic agent with quinidine-
like and mild sympatholytic and calcium entry blocking
*(2' -(-2-hydroxy-3-propylamino-propoxy)-3-phenylpropiophenone)
marketed since 1977 in Germany as Rytmonorm by Knoll AB.
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ters/min per nr' before and 2.3 ± 0.7 liters/min per m2
after; p < 0.001). None of the patients were symptomatic
from these changes.
In group A, propafenone did not affect the induci-
bility of ventricular tachycardia except for one patient
whosearrhythmia was sustained before and became non-
sustained after propafenone. In group B, sustained ven-
tricular tachycardia became noninducible in three pa-
tients and nonsustained in two patients, and nonsustained
ventricular tachycardia became noninducible in one pa-
tient after propafenone. Therefore, an appropriate load-
ing dose of intravenous propafenone such as 2 mg/kg
followed by 2 mg/min infusion may be given safely and
may suppress ventricular tachycardia. Propafenone may
be a useful addition to currently available antiar-
rhythmic agents.
effects (2). In the oral or intravenous form, it has been
reported (3,4) to be well tolerated and very effective in
suppressing frequent ventricular premature beats, with com-
plete or greater than 90% reduction in 50 to 80% of patients.
To define the electrophysiologic and hemodynamic ef-
fects of intravenous propafenone, we studied 28 patients
with recurrent ventricular tachycardia. The findings suggest
that propafenone may have mild cardiac depressant effects.
However, an appropriate dose of intravenous propafenone
may be effective in suppressing ventricular tachycardia in
certain patients.
Methods
Patients (Table 1). Twenty-eight patients with recurrent
episodes of ventricular tachycardia were enrolled in the study.
There were 25 men and 3 women, ranging in age from 18
to 71 years (mean 58). Twenty-one patients had athero-
sclerotic heart disease (19 with prior myocardial infarction
and 2 with ventricular aneurysm), 2 patients had congestive
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cardiomyopathy, 2 patients had hypertensive cardiovascular
disease, I patient had rheumatic valvular disease and 2
patients had no clinical evidence of structural heart disease
except for the rhythm disturbance. All these patients had
recurrent episodes of either sustained or nonsustained ven-
tricular tachycardia documented by electrocardiogram. Dur-
ing ventricular tachycardia, all patients were symptomatic
with palpitation, dizziness, syncope or angina pectoris. Four
patients had aborted sudden death. Conventional antiar-
rhythmic agents had proven ineffective clinically in all 28
patients, who had tried an average of 2.7 ± 1.0 agents.
Testing by programmed ventricular stimulation of at least
one conventional agent (generally intravenous procainam-
ide) had been unsuccessful in eight patients and eight pa-
tients also could not tolerate one or more conventional agents
because of side effects. In five patients, a clinical trial of
experimental agents had also failed.
Electrophysiologic study. All patients gave informed
consent and studies were performed in a nonsedated, post-
absorptive state. All antiarrhythmic agents had been with-
held for more than five half-lives.
Catheter placement and recordings. A quadripolar elec-
trode catheter was introduced into the right femoral vein
and advanced across the tricuspid valve to record the His
bundle potential. Another quadripolar electrode catheter was
likewise advanced by way of the right femoral vein and
placed in the high right atrium for programmed atrial stim-
ulation or in the right ventricle for programmed ventricular
stimulation. The intracardiac electrograms were simulta-
neously displayed with surface electrocardiographic leads
V I, I and III on a multichannel oscilloscope (Electronics
for Medicine, VR-12). Recordings were made at a paper
speed of 50 or 100 mm/s , using filter frequency settings of
30 to 500 Hz. Throughout the study, the blood pressure was
monitored by way of a femoral artery line.
Pacing and extrastimulation. A programmed digital
stimulator (Bloom & Associates) was used to deliver elec-
trical impulses of 2.0 ms duration at 2 to 2.5 times diastolic
threshold. The study protocol consisted of incremental pac-
ing and extrastimulation as described previously (5). During
extrastimulation, the right atrium or right ventricle was driven
at one or more cycle lengths (S,Sd (usually 500 and 400
ms). An atrial or ventricular premature beat (52) was intro-
duced from late diastole at progressively shorter coupling
intervals (S,S2) after every eighth paced beat until atrial or
ventricular refractoriness was encountered.
If a single ventricular premature stimulus (S2) failed to
elicit ventricular tachycardia, timed double or triple ven-
tricular stimuli were delivered. The protocol was continued
until it evoked ventricular tachycardia or until all extrastim-
uli failed to evoke a ventricular response (6). If pro-
grammed right ventricular stimulation failed to evoke ven-
tricular tachycardia, a bipolar electrode catheter was introduced
from the right femoral artery and placed in the left ventricle.
The same study protocol was then used in the left ventricle
for induction of ventricular tachycardia.
Hemodynamic study and intravenous administration
of propafenone. After spontaneous or electrical termina-
tion of ventricular tachycardia to normal sinus rhythm, the
right ventricular electrode catheter was withdrawn and re-
placed with a Swan-Ganz catheter for hemodynamic study,
during which control right atrial, pulmonary artery and pul-
monary capillary wedge pressures, cardiac index, pulmo-
nary vascular resistance and systemic vascular resistance
were measured.
Propafenone was given intravenously at a loading dose
of 2 mg/kg of body weight over a 10 minute period in all
28 patients. Subsequently, group A, the first 14 patients,
received a continuous infusion of propafenone at I mg/min,
and group B, the subsequent 14 patients, received a con-
tinuous infusion of propafenone at 2 mg/min. During the
continuous infusion, the effects of propafenone on hemo-
dynamic variables were assessed. The Swan-Ganz catheter
was then withdrawn and replaced with the previous catheter
for repeat programmed atrial and ventricular stimulation.
Blood samples were obtained before and during propafenone
infusion for determination of plasma concentrations (7).
Definition of terms. Sinus node recovery time, sino-
atrial conduction time and atrioventricular (AV) conduction
intervals and refractory periods were defined and measured
as conventionally described (8,9).
Inducibility of ventricular tachycardia was considered
positive only if the induced repetitive ventricular beats were
of the intraventricular reentrant type. Bundle branch reen-
trant beats (10) were not considered a positive response and
were excluded from analysis. Sustained ventricular tachy-
cardia was defined as ventricular tachycardia lasting for
longer than 30 seconds or requiring electrical intervention
before that time because of circulatory collapse. Nonsus-
tained ventricular tachycardia was defined as ventricular
tachycardia of at least six beats in duration, terminating
spontaneously within 30 seconds.
A favorable response was defined as one in which base-
line sustained ventricular tachycardia became nonsustained
or noninducible, or in which nonsustained ventricular tachy-
cardia became noninducible after drug administration.
Statistical analysis. Sinus node recovery time, sino-
atrial conduction time, AV conduction intervals and refrac-
tory periods and hemodynamic variables were expressed as
mean ± I standard deviation (SD). Paired data were ana-
lyzed using the two-tailed Student's t test. Unpaired data
were analyzed using the unpaired Student's t test. A prob-
ability (p) value of 0.05 or less was considered significant.
Results
Plasma propafenone concentration. At the end of the
loading dose of propafenone (2 mg/kg), which was given
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Table 1. Clinical Profile
Age (yrj
Case &Sex Cardiac D.iagnosis VT Symptoms Previous Therapy
I 68M ASHD. HMI Aborted sudden death Q. Pa. PI. Am
2 63M ASHD. HMt Syncope Q. Pa. D
3 63M ASHD. HMI Syncope Pa. PI. B. L
4 71M ASHD. HMI Dizziness Pa. PI. B. L
5 42M RHD Aborted sudden death Q
6 60M ASHD. HMI Syncope Q. E
7 64M ASHD. HMI Dizziness Q. Pa. PI
8 60M ASHD. HMI Syncope Q. Pa. D
9 IBM None Palpitation Pa. D
10 67M ASHD. HMI Aborted sudden death Q. Pa
II 64M ASHD. HMI Palpitation and chest pain Q
12 49M ASHD. HMI Aborted sudden death Q. Pa. D. Pn
13 67M ASHD. HMI Dizziness Q. Pa. D. PI
14 65M ASHD. HMI Syncope Q. Pa. L
15 63F Cardiomyopathy Syncope Q. Pa. D
16 65M ASHD. HMI Dizziness Q. Pa. D. PI. L. Me
17 62M Hypertension Syncope Pa
18 63M ASHD. HMI Palpitation Q. PI
19 62M ASHD. HMI Syncope Q. D. PI. L
20 60M ASHD. HMI Palpitation Q. Pa. D
21 61M ASHD. HMI Syncope Pa. Am
22 65M ASHD. HMI Palpitation and chest pain Pa. D. Pn
23 53M Cardiomyopathy Dizziness Q. Pa
24 25F None Palpitation Q. Pa. PI
25 52M ASHD. HMI Chest pain Pa. L. B
26 63F ASHD. HMI Palpitation Q. Pa. D. L
27 66M ASHD. HMI Dizziness Q. Pa. D
28 69M Hypertension Dizziness Q. Pa
Am = amiodarone: ASHD = arteriosclerotic heart disease: B = bretylium: D = disopyramide: E = encainide: F = female: HMI = healed
myocardial infarction: L = lidocaine: M = male: Me = rnexiletine: Pa = procainarnidc: PI = propranolol: Pn = phenytoin: Q = quinidine: RHD =
rheumatic heart disease: VT = ventricular tachycardia.
over a 10 minute period, the plasma propafenone levels
were similar in both groups of patients (2,624 ± 1,624
nglml in group A and 2,587 ± 1,186 nglml in group B; p
= not significant [NSJ). Continuous propafenone infusion
was initiated at the end of the loading dose. Ten minutes
later, the plasma levels were still comparable (1.220 ± 450
ng/ml in group A [propafenone infusion rate 1 mg/min ] and
1,494 ± 490 ng/rnl in group B [infusion rate 20 rng/min];
p = NS). At this time, repeat measurements of hemody-
namics and AV conduction patterns were made. Twenty
minutes after the initial loading dose, repeat programmed
electrical stimulation was performed. The plasma propa-
fenone concentration was higher in group B (1,447 ± 347
ng/m\) than in group A (934 ± 381 ng/rnl ; p < 0.05). The
difference persisted up to completion of programmed elec-
trical stimulation, which occurred about 50 minutes after
the loading dose of propafenone (959 ± 442 ng/ml in group
A and 1,564 ± 578 nglml in group B; p < 0.05).
Sinus node function (Table 2). There was no signifi cant
change in the spontaneous sinus cycle length (842 ± 172
ms before and 857 ± 165 ms after propafenone: p = NS)
and sinoatrial conduction time (198 ± 123 ms before and
163 ± 79 ms after propafenone; p = NS).
Refractory periods (Table 2). There was a significant
increase in the atrial effective refractory period (251 ± 50
ms before and 287 ± 74 ms after propafenone; p < 0.05)
but not the atrial functional refractory period (295 ± 30 ms
before and 317 ± 78 ms after propafenone: p = NS). The
AV nodal effective and functional refractory periods were
both significantly prolonged (324 ± 74 and 448 ± 68 ms,
respectively. before and 364 ± 95 and 484 ± 77 ms after
propafenone: both p < 0.0 I). The effective refractory period
of the right ventricle was slightly increased (223 ± 32 ms
before and 244 ± 32 ms after propafenone), but the change
did not reach statistical signifi cance.
AV conduction intervals (Table 3). Propafenone sig-
nifi cantly prolonged the AV nodal conduction time (AH
interval 95 ± 19 ms before and 11 0 ± 28 ms after pro-
pafenone: p < 0.00 I). His-Purkinje conduction time (HV
interval 48 ± lams before and 53 ± 10 ms after propa-
fenone. p < 0.00 I) and intraventricular conduction time
(QRS duration 120 ± 23 ms before and 135 ± 27 ms after
propafe none; p < 0.00 I). There was also a slight prolon-
gation of the QTc (QT/V R-R) interval (422 ± 42 ms before
and 425 ± 40 ms after propafenone) but the change did
not reach statistical significance.
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(ms) (rns) (ms) (%) p Value
SCL 842 ± 172 857 ± 165 15 2 NS
CSNRT 319 ± 162 387 ± 210 68 21 NS
SACT 198 ± 123 163 ± 79 -35 -18 NS
AFRP 295 ± 30 317 ± 78 32 II NS
AERP 251 ± 50 287 ± 74 36 15 <0.05
AVNFRP 448 ± 68 484 ± 77 36 8 <0.01
AVNERP 324 ± 74 364 ± 95 40 12 <0.01
RVERP 233 ± 32 244 ± 32 II 5 0.05 < P < 0.1
*Values expressed as mean ± standard deviation. AERP = atrial effective refractory period; AFRP = atrial functional refractory period; AV =
atrioventricular; AVNERP = AV nodal effective refractory period; AVNFRP = AV nodal functional refractory period; CSNRT = corrected sinus nodal
recovery time; NS = not significant; p = probability; RVERP = right ventricular effective refractory period; SACT = sinoatrial conduction time; SCL
= sinus cycle length.
Hemodynamics (Table 4). Propafenone did not change
the mean arterial blood pressure (97 ± 14 mm Hg before
and 96 ± 14 mmHg after propafenone; p = NS), but
significantly increased right atrial, pulmonary artery and
pulmonary capillary wedge pressures (5 ± 3, 17 ± 6 and
9 ± 5 mm Hg, respectively, before and 6 ± 4, 22 ± 8
and 14 ± 6 mm Hg, respectively, after propafenone; p <
0.05, < 0.01 and < 0.001, respectively). The cardiac index
was mildly decreased (from 2.6 ± 0.8 before to 2.3 ± 0.7
liters/min per rrr' after propafenone; p < 0.001). The sys-
temic and pulmonary vascular resistances were both in-
creased (1,610 ± 48 and 300 ± 110 dynes-s-cm t ", re-
spectively, before and 1,870 ± 500 and 470 ± 250
dynes-s-cmt ", after propafenone; both p < 0.001). None
of the patients were symptomatic from these changes. One
patient (Case 4) with prior myocardial infarction developed
a marked increase in pulmonary capillary wedge pressure
(from 10 to 32 inm Hg), pulmonary artery pressure (from
31/5 to 55/30 mm Hg) and right atrial pressure (from 6 to
17 mm Hg) accompanied by a decrease in cardiac index
(from 1.9 to 1.4 liters/min per rrr'). The patient remained
asymptomatic but consequently did not undergo repeat pro-
grammed electrical stimulation. These hemodynamic alter-
ations induced by propafenone returned to baseline after
intravenous furosemide treatment.
Inducibility of ventricular tachycardia. Group A (J3
patients). Nine patients (Cases 1, 3, 6 to 9, 11, 12 and
14) had inducible sustained ventricular tachycardia in the
Table 3. Atrioventricular Conduction Intervals
baseline state. Ventricular tachycardia remained inducible
and sustained in eight patients and became nonsustained in
one patient (Case I) after intravenous propafenone. The
remaining four patients (Cases 2,5, 10 and 13) had inducible
nonsustained ventricular tachycardia in the baseline state.
Nonsustained ventricular tachycardia remained inducible in
these latter four patients. However, the cycle length of ven-
tricular tachycardia was prolonged in 10 patients and re-
mained unchanged in 3 patients. Overall, the cycle length
of ventricular tachycardia increased from 290 ± 88 to 357
± 117 ms (p < 0.001) (Table 5; Fig. i).
Group B (14 patients). Eleven patients (Cases 16 to 18,
20 to 23 and 25 to 28) had inducible sustained ventricular
tachycardia in the baseline state. After intravenous propa-
fenone administration, sustained ventricular tachycardia be-
came noninducible in three patients (Cases 16, 17 and 20)
(Fig. 2), became nonsustained in two patients (Cases 18
and 23) and remained inducible and sustained in six patients
(Cases 21, 22 and 25 to 28). The remaining three patients
had inducible nonsustained ventricular tachycardia in the
baseline state. After propafenone, ventricular tachycardia
became noninducible in one patient (Case 24), became in-
ducible and sustained in one patient (Case 19) and remained
inducible and nonsustained in one patient (Case 15).
Follow-up. The seven patients (Cases I, 16, 17, 18, 20,
23 and 24) who had a favorable response to intravenous
propafenone continued oral propafenone (600 to 1,200
mg/day). Six (85%) of these seven had remained asymp-
Control* Propafenone*
Difference
Interval (ms) (ms) (ms) (%) p Value
Ai-! 95 ± 19 110 ± 28 15 16 <0.001
HV 48 ± to 53 ± 10 5 to <0.001
PR 169 ± 21 198 ± 26 29 17 <0.001
QRS 120 ± 23 135 ± 27 15 13 <0.001
QT, 422 ± 42 425 ± 40 3 I NS
*Values expressed as mean ± standard deviation. NS = not significant; p = probability.
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Control* Propafenone* (o/c) p Value
BP(mm Hg) 97 ± 14 96 ± 14 -I -I NS
RA (mm Hg) 5 ± 3 6 ± 4 I 20 <0.05
PA (mm Hg) 17 ± 6 22 ± 8 5 29 <0.01
PCW (mm Hg) 9 ± 5 14 ± 6 5 55 <0.001
HR (beats/min) 71 ± 17 70 ± 17 -I NS
CI (liters/min perm2) 2.6 ± 0.8 2.3 ± 0.7 -0.3 -12 <0.001
SVR (dyness-cm t ') 1,610 ± 480 1,870 ± 500 260 16 <0.001
PVR (dynes-s-cm- 5) 300 ± 110 470 ± 250 170 56 <0.001
'Mean values ± standard deviation. BP = mean arterial blood pressure; CI = cardiac index; HR = heart rate; NS = not significant; p = probability;
PA = mean pulmonary artery pressure; pew = mean pulmonary capillary wedge pressure; PVR = pulmonary vascular resistance; RA = mean right
atrial pressure; SVR = systemic vascular resistance.
tomatic after 11.4 ± 3.9 months. One patient (Case I) had
one episode of nonsustained ventricular tachycardia and was
subsequently treated with oral amiodarone.
Of the patients who had no favorable responses to intra-
venous propafenone, four (Cases 3, 12, 13 and 22) were
given a trial of oral propafenone as they had had no serious
symptoms such as syncope or cardiac arrest associated with
the occurrence of ventricular tachycardia. Two patients (Cases
12 and 13) became asymptomatic for 15.8 ± 0.3 months.
One patient (Case 22) developed fast sustained ventricular
tachycardia after 7 days of oral propafenone therapy and
was susbsequently treated with oral amiodarone. Another
patient (Case 3) had documented slow ventricular arrhyth-
mia (100 to 120 beats/min) that was tolerated clinically.
Side effects. Of the II patients treated with oral pro-
pafenone, 7 developed transient metallic taste, 2 developed
asymptomatic elevation of antinuclear antibody titers, I de-
veloped abdominal discomfort and I with a family history
of seizure disorder developed seizures, requiring reduction
of the propafenone dosage.
A
500 260 200 260
500 260 200 250






Figure 2. Case 17, group B (propafenone infusion 2 mg/min).
A, Induction of sustained ventricular tachycardia in the control
state before (PRE) propafenone, The tachycardia cycle length
was 220 ms. The tachycardia was induced from the right ventric-
ular outflow tract with three extrastimuli (52,53,54) , B, Pro-
grammed ventricular stimulation in the same patient after (POST)
propafenone. The tachycardia was not inducible from the same
site with up to three extrastimuli or stimulation from the right or
left ventricular apex. S, = pacing stimulus from the patient's




Effects on AV conduction system. Propafenone sig-
nificantly prolonged the atrial effective refractory period,








Figure 1. Case 6, group A (propafenone infusionrate I mg/min).
A, Induction of sustained ventricular tachycardia in the control
state before (PRE) propafenone. The tachycardiacycle length was
280 rns. The tachycardia was induced from the right ventricular
apex with two extrastimuli (S2,S3). HRA = high right atrial in-
tracardiac recording; VI, I and III = standard surface electrocar-
diographic leads. B, Inductionof sustainedventriculartachycardia
after (POST) propafenone. The tachycardia cycle length was 370
ms. This was inducedfrom the right ventricularoutflowtract with
three extrastimuli (S2, S3, S4). Programmed stimulation from the
right ventricular apex did not induce sustained tachycardia.
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interval) and lengthened both the effective and the functional
refractory periods of the AV node (Table 2). These findings
may explain its efficacy in the suppression of certain types
of supraventricular tachyarrhythmias (II). The extent to
which its sympathicolytic and calcium entry blocking effects
contributed is uncertain.
Propafenone has quinidine-like pharmacologic proper-
ties. These were reflected by prolongation of the His-Pur-
kinje conduction time (HV interval) and the QRS duration
(Table 3).
Effects on hemodynamics. Hemodynamically, intra-
venous propafenone significantly elevated pulmonary cap-
illary wedge, pulmonary artery and right atrial pressures.
The cardiac index was decreased and pulmonary and sys-
temic vascular resistances were increased (Table 4). These
findings could be seen in patients in both group A (propa-
fenone infusion rate I mg/min) and group B (infusion rate
2 mg/min) and were in accordance with reports by other
investigators (12,13). Although these effects are mild and
generally well tolerated, we recommend that propafenone
be given cautiously in patients with compromised left ven-
tricular function.
Effects on ventricular tachycardia. The antiar-
rhythmic effects of intravenous propafenone were reflected
by slowing of the rate of ventricular tachycardia and by
suppressing the inducibility of ventricular tachycardia (Ta-
ble 5, Fig. I and 2). Intravenous propafenone appeared to
be more efficacious in suppressing the inducibility of ven-
Table 5. Ventricular Tachycardia Induction Before and After Propafenone
Pre Post
Cycle Length Mode of Cycle Length Mode of
Case VT (rns) Induction VT (ms) Induction
Group A
\ 5 265 RV 54 N5 400 RV 52, spontaneous
2 N5 \85 RV 54 N5 195 RV 54
3 5 500 RV 53 5 590 RV 52
4*
5 N5 240 RV 54 N5 250 RV 54
6 5 295 RV 53 5 395 RV 54
7 5 420 RV 53 5 520 RV 52
8 5 260 RV 53 5 265 RV 5,
9 5 315 RV 52 5 410 Mechanical
10 N5 230 RV 54 N5 245 RV 54
1\ 5 310 RV OP 5 440 RV 54
\2 5 200 RV 54 5 265 RV 54
13 NS 280 RV 52 N5 310 RV 54
14 5 250 RV 54 5 350 RV 54
Mean 290 357
± standard ± 88 ± 117
deviation
Group B
15 N5 240 LV 52 N5 280 LV 54
16 5 400 RV 53 NI RV.LV
17 5 195 RV 54 NI RV,LV
18 5 220 LV 54 N5 380 LV, 52
19 N5 365 RV 54 5 330 RV,54
20 5 175 RV 54 NI RV,LV
2\ 5 220 RV 54 5 300 RV 54
22 5 300 RV 53 5 520 RV 52
23 5 200 RV 53 N5 250 LV 54
24 N5 167 RV 53 NI RV,LV
25 5 300 RV OP 5 370 RV 5,
26 5 280 RV 54 5 375 RV OP
27 5 330 RV 53 5 450 RV 5,
28 5 290 RV 53 5 200 RV 5,
Mean 275 346
± standard ± 53 ± 95
deviation
*Excludedbecause of hemodynamic reasons (see text). LV = left ventricle; NI = noninducible: N5 = nonsustained; OP = overdrive pacing; RV
= right ventricle; 5 = sustained; 52 = with one extrastirnuli; 5, = with two extrastirnuli; 54 = with three extrastimuli; VT = ventriculartachycardia.
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tricular tachycardia in patients in group B than in patients
in group A. Only I of the 13 patients in group A responded
compared with 6 (43%) of the 14 patients in group B. Of
these six patients, four patientshad no inducible ventricular
tachycardia after intravenous propafenone. Group A and B
patients were comparable in age (59 ± 14 versus 59 ± II
years; p = NS), cardiac disease and baseline cycle length
of ventricular tachycardia (290 ± 88 versus 275 ± 53 ms;
p = NS). Therefore, we attributed the higher success rate
of suppression of ventricular tachycardia inducibility to the
use of a higher infusionrate (2 mg/min) in group B patients.
This was supported by the finding of a significantly higher
plasmapropafenone level in group B thanin group A patients.
When evaluating antiarrhythmic effects of intravenous
propafenone, several factors should be considered. First,
we studied patients (both groups A and B) who had already
failed to respondto conventional antiarrhythmic agents clin-
ically. The success rate of intravenous propafenone in sup-
pressing the inducibility of ventriculartachycardiamaycon-
ceivably be higher in patients who are not already a
" refractory" group. Second, we used a rather aggressive
protocolof programmed electrical stimulation; this involved
three ventricular sites (two right ventricular and one left
ventricular), two cycle lengths and up to three ventricular
extrastimuli.
Third , the dosage employed may be another important
factor. In a recent study by Karagueuzian et al. (\4) , pro-
pafenone was noted to be successful in abolishing sponta-
neous ventricular tachycardia in an acutely infarcted canine
model. The loadingdose was 4 mg/kg and the infusion rate
was 2.2 mg/kg per min, achieving an average plasma con-
centration of 3 /-Lg/ml. Understandably, the anatomic sub-
strate and the mode of arrhythmia induction were different
from ours. Nonetheless, it is quite probable that a high
success rate may be attained with a higher dosage. Further
studies are necessary to define the optimal clinical dosage
of propafenone.
Clinical implications. Propafenone is a new antiar-
rhythmic agent. Intravenous infusion of propafenone at 2
mg/kg as a loading dose followed by an infusion rate of 2
mg/min is safe, and may prevent induction of sustained or
nonsustained ventricular tachycardia in patients in whom
conventional antiarrhythmic drugs failed clinically. How-
ever, propafenone , like most other antiarrhythmic agents.
may have cardiac depressant effects. It should be given
cautiously in patients with compromised left ventricular
function . Assessment of the clinical efficacyof its oral form
needs long-term follow-up studies.
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